Pacs Group, INC 10-Q quarterly reports

PACS Group, Inc. announced a significant increase in revenue and operating income for the second quarter of 2026, driven by facility expansion and improved occupancy, while also disclosing ongoing regulatory investigations and material weaknesses in internal controls.

PACS Group, Inc. announces significant revenue growth and improved profitability in its first quarter of 2026, driven by increased patient days and occupancy rates.

PACS Group announced significant revenue and net income increases for Q3 2025, alongside ongoing regulatory investigations and identified material weaknesses in internal controls.

PACS Group reported significant revenue and net income increases for Q2 2025, driven by facility expansion, but faces multiple ongoing regulatory and legal investigations, material weaknesses in internal controls, and credit facility forbearance.

PACS Group reports significant revenue growth in Q1 2025, driven by facility expansion, but faces ongoing SEC and DOJ investigations and internal control weaknesses.

PACS Group restates prior financial statements, reveals material weaknesses in internal controls, and faces multiple government and SEC investigations, alongside a CFO resignation.

PACS Group's Q2 2024 results show revenue growth driven by acquisitions, but also a net loss due to increased operating expenses and stock-based compensation.

PACS Group has filed an amendment to its quarterly report to correct an administrative error regarding the number of outstanding shares.

PACS Group's first quarter 2024 results show significant revenue growth driven by strategic acquisitions and increased patient volume.